Jay T. Backstrom Exercises Options at Agios Pharmaceuticals Inc (AGIO) — SEC Form 4, Jul 10, 2026

SEC Form 4 · No Market Transaction

Option Exercise

Derivative exercise — no open market transaction.

Reporting Owner

Jay T. Backstrom

Director

TXN 2026-07-08 · FILED 2026-07-10

Equity Position 1.45K sh 0 → 1,447

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Agios Pharmaceuticals Inc

AGIO CIK 0001439222

Reporting Owner

Name	Relationship
Jay T. Backstrom CIK 0001796398	Director

Jay T. Backstrom at Agios Pharmaceuticals Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at Agios Pharmaceuticals Inc

2026-06-23	Award	—	View
2025-07-10	Award	—	View

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common stock	2026-07-08	A - Award/Grant	1,447 A	$0.00	—	1,447	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Restricted stock unitsF1 F2 F2		2026-07-08	M - Exercise	1,447 D	$0.00		1,447 Common stock	Direct

Footnotes (2)

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Show more
F2: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Agios Pharmaceuticals Inc

GET /v1/forms/4/0001439222-26-000112 API docs